An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.

After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.

Of the big oncology deals since 2016, there are still plenty that could go either way.

A look at big oncology deals since 2016 finds outright success stories hard to come by.